Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Cash & Current Investments (2023 - 2025)

Historic Cash & Current Investments for Connect Biopharma Holdings (CNTB) over the last 3 years, with Q3 2025 value amounting to $54.8 million.

  • Connect Biopharma Holdings' Cash & Current Investments changed N/A to $54.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.8 million, marking a year-over-year change of. This contributed to the annual value of $93.7 million for FY2024, which is 2076.95% down from last year.
  • Latest data reveals that Connect Biopharma Holdings reported Cash & Current Investments of $54.8 million as of Q3 2025.
  • Connect Biopharma Holdings' Cash & Current Investments' 5-year high stood at $118.3 million during Q4 2023, with a 5-year trough of $54.8 million in Q3 2025.
  • Its 3-year average for Cash & Current Investments is $87.8 million, with a median of $84.0 million in 2025.
  • In the last 5 years, Connect Biopharma Holdings' Cash & Current Investments skyrocketed by 3500.23% in 2024 and then crashed by 3485.94% in 2025.
  • Connect Biopharma Holdings' Cash & Current Investments (Quarter) stood at $118.3 million in 2023, then fell by 20.77% to $93.7 million in 2024, then crashed by 41.56% to $54.8 million in 2025.
  • Its last three reported values are $54.8 million in Q3 2025, $71.8 million for Q2 2025, and $84.0 million during Q1 2025.